Q3 2023 Earnings Forecast for Agilent Technologies, Inc. (NYSE:A) Issued By SVB Leerink

Posted by Defense World Staff on May 25th, 2023

Agilent Technologies, Inc. (NYSE:A – Get Rating) – Stock analysts at SVB Leerink decreased their Q3 2023 earnings estimates for shares of Agilent Technologies in a research report issued to clients and investors on Tuesday, May 23rd. SVB Leerink analyst P. Souda now anticipates that the medical research company will earn $1.36 per share for the quarter, down from their previous estimate of $1.44. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.68 per share. SVB Leerink also issued estimates for Agilent Technologies’ Q4 2023 earnings at $1.63 EPS, FY2023 earnings at $5.63 EPS, Q1 2024 earnings at $1.42 EPS, Q2 2024 earnings at $1.39 EPS, Q3 2024 earnings at $1.50 EPS, Q4 2024 earnings at $1.68 EPS and FY2024 earnings at $5.99 EPS.

Several other equities analysts have also recently commented on the stock. Stifel Nicolaus cut their target price on shares of Agilent Technologies from $153.00 to $135.00 and set a “hold” rating for the company in a research note on Wednesday. Evercore ISI dropped their price objective on shares of Agilent Technologies from $150.00 to $126.00 and set an “outperform” rating for the company in a research note on Wednesday. TD Cowen dropped their price objective on shares of Agilent Technologies from $168.00 to $145.00 and set an “outperform” rating for the company in a research note on Wednesday. Citigroup dropped their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, SVB Securities dropped their price objective on shares of Agilent Technologies from $170.00 to $145.00 and set an “outperform” rating for the company in a research note on Wednesday. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $151.35.

Agilent Technologies Price Performance

NYSE:A opened at $120.99 on Thursday. The stock has a market cap of $35.78 billion, a P/E ratio of 27.31, a PEG ratio of 1.89 and a beta of 1.03. Agilent Technologies has a one year low of $112.52 and a one year high of $160.26. The company has a fifty day moving average price of $133.87 and a 200 day moving average price of $144.11. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.11 and a quick ratio of 1.53.

Agilent Technologies (NYSE:A – Get Rating) last released its earnings results on Tuesday, May 23rd. The medical research company reported $1.27 EPS for the quarter, beating the consensus estimate of $1.26 by $0.01. The firm had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.09% and a return on equity of 30.35%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.13 EPS.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds have recently added to or reduced their stakes in the stock. Natixis Investment Managers International grew its holdings in Agilent Technologies by 2.0% during the 4th quarter. Natixis Investment Managers International now owns 3,245 shares of the medical research company’s stock worth $486,000 after acquiring an additional 65 shares during the last quarter. Pinnacle Associates Ltd. grew its holdings in Agilent Technologies by 1.1% during the 4th quarter. Pinnacle Associates Ltd. now owns 5,965 shares of the medical research company’s stock worth $893,000 after acquiring an additional 67 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Agilent Technologies by 8.8% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 837 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 68 shares during the last quarter. First Command Financial Services Inc. boosted its stake in shares of Agilent Technologies by 19.4% in the 1st quarter. First Command Financial Services Inc. now owns 461 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 75 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Agilent Technologies by 34.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 298 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 77 shares during the last quarter.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Investors of record on Monday, July 3rd will be given a dividend of $0.225 per share. This represents a $0.90 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend is Friday, June 30th. Agilent Technologies’s dividend payout ratio (DPR) is currently 20.32%.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.